Skip to main contentSkip to footer
A finger pointing at a scan
Brighton & Sussex Medical School

staff profiles

BSMS > About BSMS > Contact us > Staff > Dr Chi Eziefula

Dr Chi Eziefula

Dr Chi Eziefula

Dr Chi Eziefula (MBBS MA MRCP FRCPath)

Senior Lecturer in Infectious Diseases
T: +44 (0)1273 872700
Location: Ground Floor, BSMS Medical Research Building, University of Sussex, Falmer, Brighton, BN1 9PX

DA: Debbie Miller
T: +44(0)1273 877889

Area of expertise: Malaria epidemiology, Clinical trials, Infectious diseases, Microbiology, Tropical medicine 

Research areas: Malaria transmission-blocking, malaria elimination, malaria clinical epidemiology, falciparum malaria, migrant health, global health

Other relevant positions: Theme leader for Infection and Immunity module 101



Dr Chi Eziefula is a Senior Lecturer in Infection at Brighton & Sussex Medical School and an Honorary Consultant in Infectious Diseases and Microbiology at Brighton and Sussex University Hospitals NHS Trust. She is co-director of CORTH, Centre for Cultures of Reproduction, Technologies.

Chi combines hands on clinical care in infection, tropical medicine and medical microbiology with global health research. Completing undergraduate medical training at the University of Cambridge and University College London she rotated through St Thomas’ Hospital, University College London Hospitals (Hospital for Tropical Diseases) and University Hospitals Sussex for specialist training. She was pleased to join University Hospitals Sussex NHS Foundation Trust as their first infectious diseases registrar, helping set up the service and network within the teaching hospital. Her global health expertise has been supported by Wellcome Trust-funded research positions in Kenya, (Kilifi, KEMRI/ Wellcome Trust Research Programme), and Uganda (Bloomsbury Wellcome Trust Clinical PhD Programme in International Health). 


Chi has worked in the field of malaria research since 2005. Her doctoral work at the London School of Hygiene and Tropical Medicine evaluated a pharmacological intervention to block transmission of falciparum malaria in Uganda, conducting the first dose-finding trial for primaquine as a gametocytocidal agent, which contributed to a change in the World Health Organisation malaria treatment guidelines. Her wider research interests include migrant health and global women’s health.


Chi teaches infectious diseases, microbiology and clinical and tropical medicine to undergraduates and post-graduate doctors. She leads the Infection and Immunity theme for first year medical students. She teaches on the Scientific Basis of Infectious Diseases module and gives bedside and small group clinical teaching and laboratory-based clinical microbiology teaching to fourth year students. She has taught, examined and been an exam board member on the Diploma in Tropical Medicine and Hygiene at the London School of Hygiene and Tropical Medicine.

Selected publications

Stoneham SM, Milne KM, Nuttal E, Frew GH, Sturrock BR, Sivaloganathan H, Ladikou EE, Drage S, Phillips B, Chevassut TJT, et al. Thrombotic risk in COVID-19: a case series and case–control study, Clinical Medicine 18 May 2020 (Article)

Pett H, Bradley J, Okebe J, Dicko A, Tiono AB, Gonçalves BP, Stone W, Chen I, Lanke K, Neuvonen M, et al. CYP2D6 Polymorphisms and the Safety and Gametocytocidal Activity of Single-Dose Primaquine for Plasmodium falciparum, Antimicrobial Agents and Chemotherapy 63(10) 01 Jan 2019 (Article)

Finnerty F, George S, Eziefula AC. The health of recent migrants from resource-poor countries, Medicine (United Kingdom) 46(1):66-71 01 Jan 2018 (Article) 

Artesunate-mefloquine: a malaria treatment for African children? Eziefula AC. Lancet Infect Dis. 2016 Oct;16(10):1086-1087. doi: 10.1016/S1473-3099(16)30125-6. Epub 2016 Jul 16. No abstract available. PMID: 27430373

Glucose-6-phosphate dehydrogenase status and risk of hemolysis in Plasmodium falciparum-infected African children receiving single-dose primaquine. Eziefula AC, Pett H, Grignard L, Opus S, Kiggundu M, Kamya MR, Yeung S, Staedke SG, Bousema T, Drakeley C. Antimicrob Agents Chemother. 2014 Aug;58(8):4971-3. doi: 10.1128/AAC.02889-14. Epub 2014 Jun 9. PMID: 24913169

Low-dose primaquine for falciparum malaria. Bousema T, Eziefula AC, Pett H, Drakeley C. Lancet Infect Dis. 2014 Aug;14(8):677. doi: 10.1016/S1473-3099(14)70842-4. No abstract available. PMID: 25056018

Persistence of Plasmodium falciparum parasitemia after artemisinin combination therapy: evidence from a randomized trial in Uganda. Chang HH, Meibalan E, Zelin J, Daniels R, Eziefula AC, Meyer EC, Tadesse F, Grignard L, Joice RC, Drakeley C, Wirth DF, Volkman SK, Buckee C, Bousema T, Marti M. Sci Rep. 2016 May 20;6:26330. doi: 10.1038/srep26330. PMID: 27197604

Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether-lumefantrine in children with asymptomatic infection: a randomised, double-blind, placebo-controlled trial. Gonçalves BP, Tiono AB, Ouédraogo A, Guelbéogo WM, Bradley J, Nebie I, Siaka D, Lanke K, Eziefula AC, Diarra A, Pett H, Bougouma EC, Sirima SB, Drakeley C, Bousema T. BMC Med. 2016 Mar 8;14:40. doi: 10.1186/s12916-016-0581-y. PMID: 26952094

Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomised, controlled, double-blind, dose-ranging trial. Eziefula AC, Bousema T, Yeung S, Kamya M, Owaraganise A, Gabagaya G, Bradley J, Grignard L, Lanke KH, Wanzira H, Mpimbaza A, Nsobya S, White NJ, Webb EL, Staedke SG, Drakeley C. Lancet Infect Dis. 2014 Feb;14(2):130-9. doi: 10.1016/S1473-3099(13)70268-8. Epub 2013 Nov 13. PMID: 24239324

Study protocol for a randomised controlled double-blinded trial of the dose-dependent efficacy and safety of primaquine for clearance of gametocytes in children with uncomplicated falciparum malaria in Uganda. Eziefula AC, Staedke SG, Yeung S, Webb E, Kamya M, White NJ, Bousema T, Drakeley C. BMJ Open. 2013 Mar 26;3(3). pii: e002759. doi: 10.1136/bmjopen-2013-002759. PMID: 23535703

CLICK HERE TO elements profile >